NextCure (NASDAQ:NXTC) Stock: Insider Adar1 Capital Management, Llc Acquires 5,626 Shares

NextCure, Inc. (NASDAQ:NXTC) major shareholder Adar1 Capital Management, Llc purchased 5,626 shares of the company’s stock in a transaction that occurred on Friday, October 23rd. The shares were purchased at an average price of $4.83 per share, for a total transaction of $27,173.58. Following the transaction, the insider owned 728,045 shares of the company’s stock, valued at $3,516,457.35. This trade represents a 0.78% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Large shareholders that own 10% or more of a company’s stock are required to disclose their transactions with the SEC.

Adar1 Capital Management, Llc also recently made the following trade(s):

• On Tuesday, October 27th, Adar1 Capital Management, Llc acquired 3,553 shares of NextCure stock. The stock was purchased at an average price of $5.10 per share, with a total value of $18,120.30.
• On Monday, October 26th, Adar1 Capital Management, Llc acquired 1,672 shares of NextCure stock. The stock was purchased at an average price of $5.03 per share, with a total value of $8,410.16.
• On Friday, July 31st, Adar1 Capital Management, Llc bought 36,303 shares of NextCure stock. The shares were purchased at an average cost of $4.94 per share, for a total transaction of $179,336.82.
• On Thursday, July 30th, Adar1 Capital Management, Llc bought 292,850 shares of NextCure stock. The shares were acquired at an average price of $4.93 per share, for a total transaction of $1,443,750.50.
• On Wednesday, July 29th, Adar1 Capital Management, Llc bought 3,410 shares of NextCure stock. The shares were acquired at an average price of $5.00 per share, for a total transaction of $17,050.00.

NextCure Stock Up 10.8%

Shares of NextCure stock opened at $6.34 on Thursday. NextCure, Inc. has a twelve month low of $1.55 and a twelve month high of $15.74. The business has a 50-day moving average price of $6.10 and a 200 day moving average price of $7.96. The firm has a market cap of $22.89 million, a PE ratio of -0.73 and a beta of 1.33.

NextCure (NASDAQ:NXTC) last issued its quarterly earnings data on Thursday, August 6th. The company reported ($2.80) EPS for the quarter, missing the consensus estimate of ($1.95) by ($0.85).

Institutional Trading of NextCure

An institutional investor recently raised its stake in NextCure stock. Renaissance Technologies LLC raised its position in NextCure, Inc. (NASDAQ:NXTC) by 80.0% during the first quarter, according to its most recent filing with the SEC. The institutional investor owned 60,534 shares of the company’s stock after purchasing an additional 26,900 shares during the period. Renaissance Technologies LLC owned 1.68% of NextCure worth $647,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 42.65% of the company’s stock.

Analysts Set New Price Targets

NXTC has been the topic of several research analyst reports. HC Wainwright reiterated a “buy” rating on shares of NextCure in a research report on Thursday, August 13th. Weiss Ratings downgraded shares of NextCure from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Monday. Finally, Wall Street Zen raised shares of NextCure from a “sell” rating to a “hold” rating in a research note on Saturday, August 15th. Two analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $19.00.

About NextCure

NextCure, Inc (NASDAQ: NXTC) is a clinical-stage biotechnology company focused on developing immunomedicines for the treatment of cancer. The company’s research is aimed at identifying and targeting biological mechanisms that suppress the immune system’s ability to recognize and attack tumor cells.

NextCure’s product candidates have included NC318, an antibody designed to target Siglec-6, and NC410, a fusion protein intended to block the LAIR-1 immune-suppressive pathway. These programs have been evaluated in early-stage clinical studies involving patients with advanced solid tumors, with the goal of developing treatments that may restore or enhance anti-tumor immune responses.

Founded in 2015 and headquartered in the United States, NextCure has operated primarily as a research and development company serving the global oncology market through clinical trials and collaborations.